Harvard Apparatus Regenerative Technology, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
OQB
Harvard Apparatus Regenerative Technology, Inc. reports a significant accumulated deficit and auditor's going concern qualification, alongside delays in patient recruitment for its pivotal esophageal regeneration clinical trial, despite revenue growth in its consumer health segment.
OQB
Harvard Apparatus Regenerative Technology reports a going concern qualification due to recurring losses and the need for additional funding, while facing delays in patient recruitment for its esophageal regeneration clinical trial.
OQB
Harvard Apparatus Regenerative Technology, a clinical-stage biotech company, reported its full year 2023 results, highlighting progress in its esophageal regeneration clinical trial and the launch of longevity products.